Concepedia

Jeffrey Cohen

JC

Statistics

Publications

15

Citations

4.5K

H-Index

14

Active since

1999

Affiliations

Cleveland Clinic(Current)

Charles University

Heinrich Heine University Düsseldorf

University of Cambridge

Queen Mary University of London

Jeffrey Cohen is an author at Cleveland Clinic specializing in multiple sclerosis, multiple sclerosis therapy, and neurology.

Publications per year

1999–2020

15

Publications

15

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

, , +11

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations · Full text

, , +11

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Stephen L. Hauser, Amit Bar‐Or, Jeffrey Cohen et al. · New England Journal of Medicine · 2020 · 700 citations · Full text

, , +17

Alemtuzumab CARE-MS II 5-year follow-up

Alasdair Coles, Jeffrey Cohen, Edward Fox et al. · Neurology · 2017 · 274 citations · Full text

, , +15

Alemtuzumab CARE-MS I 5-year follow-up

Eva Havrdová, Douglas L. Arnold, Jeffrey Cohen et al. · Neurology · 2017 · 223 citations · Full text

, , +17

1–5 of 15